Wolfgang C Winkelmayer, Anthonie W A Lensing, Ravi I Thadhani, Kenneth W Mahaffey, Michael Walsh, Ákos F Pap, Stefan Willmann, Kirstin Thelen, Sophie Hodge, Alexander Solms, Sheila J M Ingham, John Eikelboom
Patients with kidney failure on hemodialysis (KF-HD) are at high risk for both atherothrombotic events and bleeding. This Phase IIb study evaluated the dose-response of fesomersen, an inhibitor of hepatic Factor XI expression, versus placebo, for bleeding and atherothrombosis in patients with KF-HD. Patients were randomized to receive fesomersen 40, 80, or 120 mg once-monthly, or matching placebo, for up to 12 months. The primary safety endpoint was a composite of major bleeding and clinically relevant non-major bleeding (MB/CRNMB)...
March 25, 2024: Kidney International